Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Epirubicin/ifosfamide/sintilimab

Leukopenia and hypothyroidism

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Li J, et al. Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report. Frontiers in Immunology 14: 1-6, Jan 2023. Available from: URL: 10.3389/fimmu.2023.1228653 Li J, et al. Favorable response to PD-1 inhibitor plus chemotherapy as first-line treatment for metastatic follicular dendritic cell sarcoma of the spleen: a case report. Frontiers in Immunology 14: 1-6, Jan 2023. Available from: URL: 10.3389/fimmu.2023.1228653
Metadaten
Titel
Epirubicin/ifosfamide/sintilimab
Leukopenia and hypothyroidism
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56835-2

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Alteplase